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Drug Clearance and Arterial Uptake After Local Perivascular Delivery
to the Rat Carotid Artery
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Objectives. We attempted to characterize how drug released
into the perivascular space enters the arterial wall and how it is
cleared from the local environment.
Background. Drug released into the perivascular space can
enter the artery either from the adventitial aspect or from the
lumen after absorption by the extraarterial capillaries and mixing
within the systemic circulation. Some investigators suggest that
this latter mechanism dominates, and they question whether local
drug release is synonymous with local deposition.
Methods. We investigated both the pathways by which adven-
titially released drug is cleared from the perivascular space and
those by which drug enters the blood vessel wall. Inulin was used
to follow drug release from implanted devices and subsequent
entry to the circulation, because of its first-pass urinary excretion.
Heparin was used to follow arterial deposition because of its
vasoactivity and tissue-binding properties. The different potential
pathways of drug entry and egress were systematically removed
and the effects on metabolism and deposition determined.
Results. Ligature occlusion of the artery did not decrease inulin
excretion or heparin deposition. Extravascular wraps designed to
shield the device from extramural capillaries reduced inulin
excretion rates 10-fold but did not alter heparin deposition into
the vessel wall. The deposition of drug after perivascular delivery
was 500 times higher than after intraperitoneal administration.
Conclusions. Although almost all the drug released into the
perivascular space is cleared through the extravascular capillar-
ies, virtually all the deposited drug diffuses directly from the
perivascular space, and little arrives from the endovascular
aspect. These data support the view that local drug release leads
directly to increased local drug concentration.
(J Am Coll Cardiol 1997;29:1645–50)
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It has been hoped for some time that the systemic toxicity of
novel vasoactive compounds could be circumvented with local
vascular drug delivery, directing potent drugs to injured blood
vessels without the potential adverse complications of systemic
administration (1,2). Polymeric and cell-based delivery systems
have been implanted perivascularly to deliver growth-
modulating compounds to arterial cells and tissues (3–5). Yet
the precise mechanisms by which the compounds travel from
perivascular devices and enter vascular tissues are still elusive,
making their pharmacokinetics difficult to assess and frustrat-
ing appreciation of their full clinical utility. For example, it
might be argued that drug released into the perivascular space
principally enters the adjacent artery from the lumen after
absorption by extramural capillaries and mixture within the
systemic circulation, rendering periarterial release functionally
identical to any other form of intravascular delivery. Moreover,
one must then reconsider the perceived advantages of local
perivascular implantation and release. On the other hand, the
success of perivascular release strategies in comparison with
modes of systemic administration suggests a physiologic advan-
tage to both local sustained release and direct delivery of drug
to the adventitial aspect of the artery (4). Elucidation of the
transport and metabolic pathways for drugs placed outside the
artery is therefore critical to optimizing release device formu-
lations and implantation regimens for maximal biologic effect.
We therefore sought to characterize the pathways by which
drug is cleared from the perivascular space and subsequently
deposited within the blood vessel wall. Drug can be cleared
from the perivascular space by transmural diffusion (pathway
a, Fig. 1a), or absorption by extraarterial microvessels (path-
way b). Extraarterial capillaries are defined as any source of
clearance outside the arterial wall proper and includes the
capillaries of skeletal muscle or other tissues and lymphatic
vessels. The relative importance of these pathways was deter-
mined by measuring the urinary excretion rate of perivascu-
larly released inulin as each route was systematically elimi-
nated. As we have previously documented (6), urinary inulin
excretion can be used as a proxy for drug entry into the general
circulation as this polysaccharide is first-pass excreted and
eliminated from plasma through the renal glomerulus without
metabolism, secretion or tubular reabsorption. Drug absorbed
by these capillaries could join the systemic circulation and
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enter the vessel wall from its endovascular aspect. This possi-
bility, as well as the potential for drug to diffuse indirectly from
the perivascular aspect, was tested by following the deposition
of heparin released from outside the blood vessel. Heparin was
chosen as a model vasotherapeutic drug because it binds
reversibly to elements of the blood vessel wall (7,8) and is a
potent inhibitor of vascular smooth muscle cell proliferation
(9–11). Heparin deposition was measured in the native unma-
nipulated state and after elimination of pathways that could
lead to endovascular administration from the systemic circula-
tion (pathway c, Fig. 1b), extraarterial capillary uptake (path-
way d, Fig. 1b) or direct diffusion from the perivascular space
(pathway e, Fig. 1b). These studies may allow for greater
understanding of local vascular drug metabolism and more
rational design of regional vascular drug therapy.
Methods
We measured the individual in vitro release kinetics of
14C-inulin or 3H-heparin from 28% (wt/vol) gels of Poloxamer
copolymer (poly(oxyethylene)-poly(oxypropylene) [Pluronic
407, BASF Wyandotte Corp. and Anti-adhesion 28, MDV
Technologies]). Poloxamer 407 solutions undergo reverse
phase gelation, remaining as free-flowing liquids until the
ambient temperature is raised above the critical threshold of
15°C, well below room and body temperature. Above this
temperature, viscosity increases markedly and the gel solidifies
into a solid mass. Erosion of, and subsequent release from,
such a gel is then prolonged, enabling use as drug depots.
Poloxamer solution containing either 14C-inulin (3.5 mCi,
1.4 mg, NEN-Dupont) or 3H-heparin (10.0 mCi, 14 mg, NEN-
Dupont) was kept in liquid form on ice (3° to 5°C), and then
100-ml aliquots were injected into a Silastic tube (inner diam-
eter [ID] 3.18 mm, Dow Corning) maintained at 23°C. The rise
in temperature from 4°C to 23°C promoted reverse phase
gelation. The resultant cylindric plug of Poloxamer was re-
moved from the tubing, placed in 50 ml of phosphate-buffered
saline solution (pH 7.4 and 37°C) under agitation, and 0.5-ml
samples were removed every 15 min for hour 1 and every
30 min for the next 4 h. All in vitro release experiments were
performed in triplicate.
Routes of clearance from the perivascular space. The
protocol conformed to the “Position of the American Heart
Association on Research Animal Use” adopted by the Asso-
ciation in November 1984, and it was approved by the Massa-
chusetts Institute of Technology Committee on Animal Care.
Sprague-Dawley female rats (275 to 325 g) were anesthetized
with an intraperitoneal injection of ketamine (50 mg/kg
body weight) and xylazine (10 mg/kg). Urinary inulin excretion
was monitored continuously through the placement of a
catheter into the bladder. The bladder, exposed after a midline
abdominal incision, was cannulated with a 20-cm poly-
ethylene tube (ID 0.58 mm, Clay Adams) and secured
with a purse-string suture. Incisions were closed, and supple-
mentary anesthesia with ketamine (12.5 mg/kg) and xylazine
(2.5 mg/kg) was administered as necessary.
The left common carotid artery was exposed and cleaned of
excess fat and fascia. Histologic and immunohistochemical
examination of arteries that had undergone similar manipula-
tion showed complete absence of vasa vasorum and no overt
damage. In one experimental group, a 100-ml dose of 14C-
inulin in 28% (wt/vol) Poloxamer solution (0.35 mCi, 0.14 mg)
kept on ice (3° to 5°C) was injected into the perivascular space.
The gel, which had remained fluid while cool, gelled immedi-
ately on contact with the artery at 37°C, conforming to the
irregular surface of the vessel (12). Urinary flow through the
bladder cannula was directed into a clean scintillation vial
every 15 min for 1 h and every 30 min for the next 3 h. In a
second experimental group, the potential for transarterial inulin
clearance was eliminated by ligating arteries at proximal and
distal sites spaced 1 cm apart (blocking pathway a, Fig. 1a).
Any inulin that traversed the wall was then trapped within the
occluded segment and could not mix with systemic circulation
for excretion. In a third group, the Poloxamer gel and extraar-
terial capillary beds were separated by a circumferential Silas-
tic sheath (ID 3.18 mm) whose ends and seam were plugged
Abbreviations and Acronyms
ANOVA 5 analysis of variance
ID 5 inner diameter
Figure 1. a, Routes of clearance from the perivascular space include
transarterial transport with entry into the lumen flow (pathway a) and
absorption by extraarterial capillaries (pathway b). b, Routes of entry
to the blood vessel wall from the perivascular space include endovas-
cular administration from the systemic circulation (pathway c) after
absorption by extraarterial capillaries (pathway d) and direct diffusion
(pathway e).
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with a silicon glue (Type A Medical Adhesive, Dow Corning).
The Poloxamer solution was injected only into the space within
the sheath, retaining arterial contact with the gel but eliminat-
ing possible capillary bed absorption of inulin (blocking path-
way b). After all of these experiments the 14C-inulin content
within each urine sample was determined by liquid scintillation
spectroscopy (1214 RackBeta, LKB-Wallac). In a fourth group
the integrity of the Silastic wrap was determined. Each of the
manipulations described for the previous two groups was
employed and both transmural and extraarterial capillary
clearance were eliminated (blocking pathways a and b, Fig. 1a).
Four rats were examined in each of the four experimental
groups. To visualize potential leaks from the seam or plugs at
the ends of this barrier, Evans blue dye (Sigma) was mixed into
the Poloxamer solution (25 mg/ml), and then injected into a
wrapped artery of an additional animal.
Routes of entry to the blood vessel wall. In a similar
fashion, drug entry and deposition into the arterial wall were
quantified with heparin-releasing Poloxamer gels fabricated as
described above. Female Sprague-Dawley rats (275 to 325 g)
were anesthetized and their left carotid arteries isolated as
before. Four animals were examined in each experimental
group. In one group, 100 ml of 3H-heparin (1.0 mCi, 1.4 mg) in
28% Poloxamer solution kept on ice (3° to 5°C) was injected
into the perivascular space of the left carotid artery. The
Poloxamer solution gelled immediately on contact with the
artery. One hour after administration of the heparin-gel, the
left carotid artery was excised, blotted to remove excess fluid,
and dipped into 100% ethanol to dissolve adhering Poloxamer
gel. The artery was dehydrated, weighed, solubilized with
0.5 ml of Soluene-350 (Packard) and counted by liquid scintil-
lation spectrometry for 3H-heparin deposition. In addition, 10-
to 60-mg tissue samples from the abdominal aorta, iliac and
femoral arteries and liver were harvested, dehydrated,
weighed, solubilized and counted. The liver was assayed in
particular because its high density of endothelial cells created
a large potential sink for heparin binding (13,14). Liver
samples were bleached to reduce color quenching of tritium by
adding 0.5 ml of hydrogen peroxide before scintillation count-
ing.
In a second experimental group, the possibility that heparin
could be deposited from blood flowing in the lumen was
eliminated by occluding the artery with proximal and distal
ligatures. Any heparin detected in the wall could have only
arrived directly from the perivascular space (blocking pathway
c, Fig. 1b). In a third group, the possibility that heparin might
enter the systemic circulation from extraarterial capillary drug
absorption was prevented with a Silastic wrap. The heparin-
Poloxamer solution was injected around the artery but inside a
silicon glue–sealed Silastic sheath (blocking pathway d). In a
fourth group, heparin deposition within the carotid artery was
quantified after the Poloxamer solution was injected into the
highly vascularized peritoneal cavity (blocking pathway e). The
contribution of direct diffusion from the perivascular space
could then be determined by comparison with data obtained
after local arterial delivery. In this group, care was taken to
remove liver samples that were not in contact with any injected
Poloxamer gel.
Statistics. All data are presented as the mean value 6
SEM. Linear regression correlation coefficients were deter-
mined for in vitro release data and for urinary inulin excretion
data. The former were compared using two-tailed t tests of
equal variance and the latter through analysis of variance
(ANOVA). Heparin deposition measurements for the various
manipulations to the carotid artery were compared through
ANOVA. All data were deemed statistically different when
p , 0.05.
Results
In vitro release kinetic profiles for inulin and heparin from
Poloxamer 407 gels cast into cylindric geometries were linear
with time and statistically indistinguishable (Fig. 2). Inulin was
administered from these gels into the perivascular space of
unmanipulated native arteries or ligature-occluded arteries
whose transarterial pathways to the systemic circulation were
removed (Fig. 1a). Rates of inulin clearance from the perivas-
cular space of these two vessels, native and occluded, were
statistically indistinguishable (Fig. 3a), implying that drug
released into the perivascular space was cleared through the
extraarterial capillaries and not through the wall of the carotid
artery into the lumen. These observations were further sup-
ported by tracking inulin excretion rates when the polysaccha-
ride was released from the perivascular space of wrapped
arteries. The wraps served as an impermeable barrier prevent-
ing drug from clearing through the extraarterial capillaries.
Inulin excretion rates from wrapped arteries were ;10-fold
lower than for native or occluded arteries, but indistinguish-
able from rates observed in arteries that were both occluded
and wrapped (Fig. 3b). Thus, the minimal amount of inulin
excretion detected with wrapped arteries reflects leakage
through imperfections in the Silastic barrier rather than trans-
Figure 2. In vitro cumulative percent release of 3H-heparin (squares)
and 14C-inulin (circles) from cylindrical Poloxamer gels. Data are
presented as average 6 SEM (n 5 3).
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mural clearance. The presence of barrier leaks was visually
detected when Evans blue dye delivered from the Poloxamer
gel extravasated from the ends of the wrap and migrated along
the artery, ultimately spreading to the capillaries in the perivas-
cular space.
Deposition of heparin released into the perivascular
space was followed as each potential pathway from release
device to the tissue— extraarterial capillary absorption, de-
livery from the general circulation and direct diffusion—was
systematically eliminated (Fig. 1b). After 1 h of release, the
amount of heparin in the carotid artery was ,1.2% of the
administered dose, 500-fold higher than in distant arteries
or the liver and not statistically altered by ligature occlusion
of the blood vessel (Fig. 4). After intraperitoneal applica-
tion of the heparin-Poloxamer gel, drug deposition in the
carotid artery was similar to that in other tissues. Drug
delivery from inside a wrap surrounding the carotid artery
did not result in statistically increased local arterial concen-
trations. In addition, concentrations in distant structures
were not diminished, because the wrap failed to eliminate
extraarterial capillary absorption.
Discussion
Although local perivascular drug delivery systems have
demonstrated successful release of a range of compounds and
achieved diverse biologic effects in injured blood vessels
(3,4,12,15–21), limitations remain both in understanding the
mechanisms of action and in optimal design of these systems.
The pharmacokinetics that result from such systems are com-
plex, as they impart large time-dependent drug concentration
gradients across vascular tissues (22). Precise elucidation of the
pharmacokinetics requires not only quantitative evaluation of
the forces that govern transport and binding within arterial
tissues but also a description of how drug arrives at the
boundary of the blood vessel wall. Transport and binding
constants have been evaluated for a model vasotherapeutic
compound, heparin, in vascular tissues (7,23); however, the
boundary conditions remain obscure. Controversy exists as to
whether drug released into the perivascular space diffuses
directly to the artery or whether drug is absorbed by capillaries
outside the artery, mixed with the systemic circulation and only
then returned to the endovascular aspect. Countless studies
have exhaustively characterized both the mechanisms and
kinetics of drug release from polymeric systems, and devices
can now be fabricated to deliver virtually any pattern of
release. However, there is a dearth of information regarding
the fate of the drug once freed. It has been further noted (24)
with other compounds that only a small fraction of the drug
released into the perivascular space can be found within the
blood vessel, suggesting that steps might be taken to increase
the efficiency of local delivery. Additional debate exists as to
whether wrapping the artery and release device within an
impermeable barrier that shields extraarterial microvessels
from the drug will improve vascular localization and further
minimize systemic levels.
Figure 3. a, Cumulative urinary excretion of 14C-inulin per amount
administered after pericarotid delivery to native arteries, occluded
arteries and arteries wrapped in order to shield the extraarterial
capillaries from the drug. b, Cumulative urinary excretion of 14C-inulin
per amount administered after pericarotid delivery with wrapped
arteries, and both wrapped and occluded arteries; the latter reflects the
leak from the wrap. Data are presented as average 6 SEM (n 5 4).
Figure 4. 3H-heparin deposition (mg of heparin per mg administered
per mg dry tissue) in the carotid artery, abdominal aorta, iliac and
femoral arteries and liver after 1 h of release. Poloxamer containing
heparin was injected into the perivascular space of carotid arteries that
were native, occluded or wrapped. Deposition in the carotid artery
after local delivery, whether native, occluded or wrapped, was ;500
times that observed after intraperitoneal (IP) injection. Data are
presented as average 6 SEM (n 5 4).
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Model pathways from the perivascular space to the blood
vessel wall. The present study was designed to show how
perivascularly released drug arrives at the arterial wall by
independently determining the relative importance of each of
the pathways by which drug leaves the perivascular space and
by which pathways it enters the blood vessel wall. We delivered
model drugs, inulin and heparin, perivascularly and observed
how the urinary excretion and arterial deposition were altered
as the pathways of vessel wall clearance and entry were
systematically eliminated, respectively. The potential routes of
drug clearance from the perivascular space are absorption by
extraarterial microvessels or transarterial diffusion directly into
the circulation (Fig. 1a), whereas the pathways to the arterial
wall are endovascular application from the circulation or direct
diffusion through the adventitial aspect (Fig. 1b). Ligature
occlusion of the blood vessel did not decrease inulin excretion
(Fig. 3a) or decrease heparin deposition (Fig. 4). Extravascular
wraps that were designed to prevent exposure of the extravas-
cular capillaries to the drug reduced inulin excretion but left
heparin deposition unchanged. However, the deposition of
heparin after perivascular delivery was much higher than for
intraperitoneal administration. The combination of these anal-
yses reveals that the overwhelming amount of perivascularly
released drug is absorbed by the extraarterial capillaries, yet
virtually all the drug found in the artery diffuses directly from
the device through the perivascular space and into the arterial
wall.
These seemingly contrary processes are neither paradoxic
nor mutually exclusive. The total surface area for absorption of
the extraarterial capillaries is much larger than that of the
carotid artery. Moreover, the transmural diffusive resistance of
the artery is much greater than that of an individual capillary,
simply because it is much thicker (23). Both of these effects
cause the vast majority of drug to be cleared by the extraarte-
rial capillaries. That all of the drug deposited in the arterial
wall comes from the perivascular space, and not from the
circulation, reflects systemic dilution far below the drug con-
centration in the perivascular interstitial fluids. Therefore,
there is a large transmural concentration gradient forcing drug
into the vessel wall from the perivascular space. These argu-
ments reflect the anatomy of the blood vessel wall and the
surrounding extraarterial capillaries, and are valid for any
compound. Therefore, the balance between transarterial trans-
port and absorption by these capillaries, to a first-order
approximation, is insensitive to differences in diffusion, parti-
tioning and binding exhibited by heparin, inulin or other
compounds. We have, therefore, combined these two results to
provide a unified qualitative model of how drug is handled by
vascular tissues and their local environments.
The rat carotid artery is thin and has few if any vasa
vasorum. In thicker arteries the transvascular resistance is
greater and transmural clearance will be even further over-
whelmed by absorption from extraarterial capillaries. How-
ever, larger arteries are vascularized by vasa vasorum (25),
which potentially absorb drug and carry it deeper into the
media, thus enhancing transmural clearance. Both increased
transvascular resistance and the contributions of vasa vasorum
are important considerations for extrapolating the results of
these studies to larger arteries.
Is there a need to wrap the device with the artery? The
potential loss of drug to extraarterial capillaries has prompted
some investigators (3,26) to advocate that perivascular drug
delivery might be more efficient if the artery and release device
were wrap-isolated with impermeable barriers. Our data show
that inulin still leaked out of wrapped spaces, even after the
ends were plugged (Fig. 3b). It is possible that the continuity of
the artery through the plug and beyond support a continuous
aqueous layer on the adventitial surface that provides a low
resistance pathway for drug to escape from within the wrap.
This leak was noted visually by administering Evans blue dye in
Poloxamer gel from within a wrap around the carotid artery
and observing the diffusion along the arterial surface. The
arterial wrap did not increase local vascular heparin concen-
trations or decrease deposition in distant structures (Fig. 4), in
part because it failed to completely eliminate extraarterial
capillary absorption. However, the wrap did slow the release of
drug from Poloxamer 407 gels, presumably by limiting the
exposure to interstitial fluids (Fig. 3). The rush to wrap arteries
and release devices should be tempered in light of evidence
that wrapping arteries can impose deleterious ischemic and
proliferative injury (27,28).
Summary. Drug was released into the perivascular space in
vivo in an attempt to settle a long-running debate on how drug
moves from local release devices to the blood vessel wall.
These studies have shown that the overwhelming majority of
drug leaves the perivascular space through the extraarterial
capillaries, and yet little enters the vessel wall from the
endovascular aspect. All of the small fraction of drug that
enters the blood vessel wall arrives by direct diffusion from the
perivascular space. In addition, placing barriers around the
device and artery does not eliminate extraarterial capillary
uptake completely, significantly diminish concentrations in
distant organs or increase the amount of drug found in the
blood vessel wall.
We thank Renata Yang and Lily Huang for their assistance in the laboratory.
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